Anti-Programmed-Death-Receptor-1 Treatment with Pembrolizumab in Ipilimumab-Refractory Advance Melanoma: a Randomized Dose-Comparison Cohort of a Phase 1 Trial

Cochereau D.; Lebbe C.

首页> 外文期刊>Oncologie. >Anti-Programmed-Death-Receptor-1 Treatment with Pembrolizumab in Ipilimumab-Refractory Advance Melanoma: a Randomized Dose-Comparison Cohort of a Phase 1 Trial

【24h】

Anti-Programmed-Death-Receptor-1 Treatment with Pembrolizumab in Ipilimumab-Refractory Advance Melanoma: a Randomized Dose-Comparison Cohort of a Phase 1 Trial

机译：依贝莫单抗难治性晚期黑色素瘤中的派姆单抗抗编程死亡受体1治疗：1期试验的随机剂量比较队列。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Oncologie.》 |2015年第3期|共2页
作者
Cochereau D.; Lebbe C.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 fre
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Anti-Programmed-Death-Receptor-1 Treatment with Pembrolizumab in Ipilimumab-Refractory Advance Melanoma: a Randomized Dose-Comparison Cohort of a Phase 1 Trial [J] . Cochereau D., Lebbe C. Oncologie. . 2015,第3期

机译：依贝莫单抗难治性晚期黑色素瘤中的派姆单抗抗编程死亡受体1治疗：1期试验的随机剂量比较队列。
2. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial [J] . RobertC., RibasA., WolchokJ.D., The Lancet . 2014,第9948期

机译：pembrolizumab在ipilimumab难治性晚期黑色素瘤中使用抗编程死亡受体1治疗：一项1期试验的随机剂量比较队列
3. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial [J] . RobertC., RibasA., WolchokJ.D., The Lancet . 2014,第9948期

机译：pembrolizumab在ipilimumab难治性晚期黑色素瘤中使用抗编程死亡受体1治疗：一项1期试验的随机剂量比较队列
4. All PUFAs Are Not Created Equal: Absence of CHD Benefit Specific to Linoleic Acid in Randomized Controlled Trials and Prospective Observational Cohorts [C] . Christopher E. Ramsden, Joseph R. Hibbeln, Sharon F. Majchrzak-Hong Inaugural Conference of the World Council on Genetics, Nutrition and Fitness for Health on the theme "Health Agriculture, Healthy Nutrition, Healthy People . 2011

机译：所有PUFA都没有创造平等：在随机对照试验中的亚油酸和预期观察队列中没有CHD益处的缺失。
5. Phase II double-blinded randomized controlled clinical trial of chondroitinase ABC by intraspinal injection for treatment of severe chronic spinal cord injury in 60 pet dogs. [D] . Hu, Hilary. 2016

机译：脊髓内注射软骨素酶ABC的II期双盲随机对照临床试验，用于治疗60只宠物狗的严重慢性脊髓损伤。
6. Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma [O] . Yousef Zakharia, Robert R McWilliams, Olivier Rixe, 2021

机译：IIO途径抑制剂Indoximod Plus Pembrolizumab治疗晚期黑素瘤的患者
7. An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer [O] . J. Spicer, M. Provencio, P. Garrido Lopez, 2019

机译：IO102和Pembrolizumab或IO102，Pembrozumab和化疗的开放标签，随机，阶段I / II试验，作为转移性非小细胞肺癌患者的一线治疗

Anti-Programmed-Death-Receptor-1 Treatment with Pembrolizumab in Ipilimumab-Refractory Advance Melanoma: a Randomized Dose-Comparison Cohort of a Phase 1 Trial

著录项

引文网络

相似文献

相关主题

期刊订阅